Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

Who May Qualify: - Ability to understand and the willingness to sign a written willing to sign a consent form document. - Age ≥ 18 years and ≤ 80 years. - Eastern Cooperative Oncology Group (ECOG) performance status 0-2. - diagnosed by tissue sample (biopsy-confirmed) advanced pancreas adenocarcinoma. - Tumor progression after at least one line of chemotherapy. - Genetic or molecular test confirmed the presence of homologous recombination deficiency. - Presence of at least of one measurable lesion in agreement to RECIST criteria. - The expected survival ≥ 3 months. - Adequate organ performance based on laboratory blood tests. - Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Who Should NOT Join This Trial: - Pregnant or nursing women. - Primary pancreatic cancer. - Patients who have received platinum or PARPi treatment. - The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas. - Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc. - Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results. - Renal insufficiency or dialysis - Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment. - Patients who are allergic to cisplatin or other platinum drugs. - Patients who are unwilling or unable to comply with study procedures. Always talk to your doctor about whether this trial is right for you.